DIM-3,5-Cl2 是一种反向 NR4A1/NR4A2 激动剂,对 NR4A1 和 NR4A2 的 KD 值分别为 7.7 μM 和 12.0 μM,其作为反向激动剂可下调促癌和促子宫内膜异位症基因产物,同时作为激动剂可增强 NR4A1/2/Sp1/Sp4 介导的 CD71 反式激活,并通过活性氧 (ROS) 生成、脂质过氧化、丙二醛 (MDA) 产生以及 GPX4、SLC7A11 表达下调诱导铁死亡 (ferroptosis),通过 PARP 和 caspase-3 剪切、BCL-2 表达下调诱导细胞凋亡 (apoptosis) 并抑制癌细胞活力,可用于三阴性乳腺癌、子宫内膜异位症和结直肠癌的研究。
产品编号: MS-O12257 纯度: 99.18% CAS No.: 2595179-74-9 分子式: C23H16Cl2N2 分子量: 391.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

DIM-3,5-Cl2 是一种反向 NR4A1/NR4A2 激动剂,对 NR4A1 和 NR4A2 的 KD 值分别为 7.7 μM 和 12.0 μM,其作为反向激动剂可下调促癌和促子宫内膜异位症基因产物,同时作为激动剂可增强 NR4A1/2/Sp1/Sp4 介导的 CD71 反式激活,并通过活性氧 (ROS) 生成、脂质过氧化、丙二醛 (MDA) 产生以及 GPX4、SLC7A11 表达下调诱导铁死亡 (ferroptosis),通过 PARP 和 caspase-3 剪切、BCL-2 表达下调诱导细胞凋亡 (apoptosis) 并抑制癌细胞活力,可用于三阴性乳腺癌、子宫内膜异位症和结直肠癌的研究。

生物实验数据

生物活性 DIM-3,5-Cl2 is an inverse NR4A1/NR4A2 agonist with KD values of 7.7 μM for NR4A1 and 12.0 μM for NR4A2 that, as an inverse agonist, downregulates pro-oncogenic and pro-endometriosis gene products while, as an agonist, enhances NR4A1/2/Sp1/Sp4-mediated CD71 transactivation, and induces ferroptosis through reactive oxygen species (ROS) generation, lipid peroxidation, malondialdehyde (MDA) production, and downregulation of GPX4 and SLC7A11 expression, induces apoptosis via PARP and caspase-3 cleavage and BCL-2 downregulation, and inhibits cancer cell viability, making it useful for research on triple-negative breast cancer, endometriosis, and colorectal cancer.
IC50 & Target NR4A2:12.0 μM (Kd), NR4A1:7.7 μM (Kd)
体外研究
(In Vitro)

DIM-3,5-Cl2 (2.5-15 μM) 可强效抑制人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞的活力。
DIM-3,5-Cl2 (7-15 μM; 24 h for MDA-MB-231, MDA-MB-468; 10-15 μM; 24 h for 4T1) 可通过诱导剪切型 PARP 和剪切型 caspase-3 的表达、下调促存活蛋白 BCL-2、全长 PARP 及全长 caspase-3,诱导人源 MDA-MB-231、MDA-MB-468 和鼠源 4T1 三阴性乳腺癌 (TNBC) 细胞发生凋亡。
DIM-3,5-Cl2 (对 MDA-MB-231、MDA-MB-468 细胞为 7-15 μM;24 h;对 4T1 细胞为 10-15 μM;24 h) 可通过下调 GPX4 和 SLC7A11 的表达、在中低浓度 (7, 10 μM) 时诱导 CD71 表达而在高浓度 (12, 15 μM) 时下调 CD71 表达,调控人源 MDA-MB-231、MDA-MB-468 和小鼠源 4T1 三阴性乳腺癌 (TNBC) 细胞中与铁死亡相关的蛋白。
DIM-3,5-Cl2 (10-12 μM; 24 h) 可在人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中下调促癌蛋白 EGFR、β1 整合素和 c-Myc。
DIM-3,5-Cl2 (12 μM; 16 h) 可在人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞中强效诱导 ROS 生成。
DIM-3,5-Cl2 (12 μM; 16 h) 可在人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞中强效诱导脂质过氧化。
DIM-3,5-Cl2 (12 μM; 24 h) 在人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中介导的 CD71、GPX4 和 SLC7A11 表达下调可被铁死亡抑制剂 Ferrostatin-1 (MS-K98895) 逆转,证实 DIM-3,5-Cl2 通过铁死亡途径发挥作用。
DIM-3,5-Cl2 (7-10 μM; 1, 2, 4, 6 h) 可时间依赖性地诱导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 CD71 蛋白及 CD71 mRNA 的表达,其中蛋白表达在 6 h 时被诱导,mRNA 表达在 4 h 时达到峰值。
DIM-3,5-Cl2 (15 μM; 24 h) 可在表达 NR4A1/NR4A2 的三阴性乳腺癌患者来源类器官 (TNBC PDxO) 模型 (BCM-HCI-3561、BCM-4175) 中诱导 CD71 蛋白表达。
DIM-3,5-Cl2 (10 μM) 可介导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 CD71 启动子活性的诱导,该作用依赖于 NR4A1 和 NR4A2 的表达,因为敲低其中任一受体均可消除该诱导作用。
DIM-3,5-Cl2 (10 μM; 4-24 h) 可时间依赖性地诱导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 Sp1、Sp4 和 CD71 的蛋白表达,且 CD71 的表达依赖于 Sp1 和 Sp4 的表达;因为敲低其中任一转录因子都会降低 CD71 的水平。
DIM-3,5-Cl2 (0.25-20 μM; 48 h) 可强效抑制 IHEEC 细胞 (IC50 = 7.34 μM) 和 IHESC 细胞 (IC50 = 5.78 μM) 的增殖,处理时间为 48 h。
DIM-3,5-Cl2 (6.5 μM; 24 h) 可显著抑制 IHEEC 和 IHESC 细胞的迁移。
DIM-3,5-Cl2 (6.5-13 μM; 24 h) 可以细胞类型特异性方式调控子宫内膜异位症相关通路蛋白的表达,下调增殖、纤维化及上皮间质转化 (EMT) 标志物,上调凋亡标志物,并降低 IHEEC 和 IHESC 细胞中的 NR4A1/NR4A2 水平。
DIM-3,5-Cl2 (13 μM; 12 h) 可降低纤维化及上皮间质转化 (EMT) 标志物 (COL1A1、N-钙黏蛋白、TWIST1) 的表达,并破坏 IHEEC 和 IHESC 细胞中的肌动蛋白丝结构。
DIM-3,5-Cl2 (5-10 μM; 24 h) 可降低人结肠癌细胞 SW480 中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。
DIM-3,5-Cl2 (2.5-7.5 μM; 24 h) 可下调人结肠癌细胞 RKO 中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。
DIM-3,5-Cl2 (2.5-7.5 μM; 24 h) 可降低 MC-38 小鼠结肠癌细胞中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。
DIM-3,5-Cl2 (7.5 μM; 3 h) 可降低 MC-38 小鼠结肠癌细胞中 NR4A1、Sp1 及 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合作用。
DIM-3,5-Cl2 (10 μM; 3 h) 可降低 SW480 人结肠癌细胞中 NR4A1、Sp1 和 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合作用。
DIM-3,5-Cl2 (7.5 μM; 3 h) 可降低人结肠癌细胞 RKO 中 NR4A1、Sp1 和 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合能力。

Western Blot Analysis

Cell Line: Human MDA-MB-231, MDA-MB-468, and mouse 4T1 triple negative breast cancer (TNBC) cells
Concentration: 7, 10, 12, 15 μM (MDA-MB-231, MDA-MB-468); 10, 12, 15 μM (4T1)
Incubation Time: 24 h
Result: Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12 μM in MDA-MB-231 cells.
Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12, 15 μM in MDA-MB-468 cells.
Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 10, 12, 15 μM in 4T1 cells.\nDecreased GPX4 and SLC7A11 protein levels at 7, 10, 12 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12 μM in MDA-MB-231 cells.
Decreased GPX4 and SLC7A11 protein levels at 7, 10, 12, 15 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12, 15 μM in MDA-MB-468 cells.
Decreased GPX4 and SLC7A11 protein levels at 10, 12, 15 μM; induced CD71 protein levels at 10, 12, 15 μM in 4T1 cells.

Western Blot Analysis

Cell Line: Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration: 10, 12 μM
Incubation Time: 24 h
Result: Decreased expression of EGFR, β1-integrin, and c-Myc in MDA-MB-231 cells.

Western Blot Analysis

Cell Line: Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration: 12 μM
Incubation Time: 24 h
Result: Ferrostatin-1 significantly inhibited compound-mediated downregulation of CD71, GPX4, and SLC7A11 in MDA-MB-231 cells.

Western Blot Analysis

Cell Line: Human MDA-MB-231 triple negative breast cancer (TNBC) cells
Concentration: 10 μM
Incubation Time: 4, 6, 24 h
Result: Knockdown of Sp1 or Sp4 alone decreased CD71 protein expression in MDA-MB-231 cells.
Induced Sp1, Sp4, and CD71 protein expression in MDA-MB-231 cells at 4, 6, and 24 h, with increasing induction observed over time.

Cell Migration Assay

Cell Line: Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration: 6.5 μM
Incubation Time: 24 h
Result: Significantly reduced migration of IHEEC and IHESC cells into the scratch wound area compared to vehicle controls, as measured by relative migration percentage.

Western Blot Analysis

Cell Line: Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration: 6.5 μM; 13 μM
Incubation Time: 24 h
Result: Significantly decreased protein levels of EGFR, mTOR, phospho-mTOR, β1-integrin, CTGF, FN, COL1A1, TWIST1, Slug, Snail, Vimentin, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHEEC cells.
Significantly increased protein levels of cleaved poly(ADP-ribose) polymerase (C-PARP) and claudin-1 in IHEEC cells.
Had no significant effect on ERβ levels in IHEEC cells.
Significantly decreased protein levels of mTOR, phospho-mTOR, β1-integrin, ERβ, CTGF, COL1A1, TWIST1, Slug, Snail, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHESC cells.
Significantly increased protein levels of C-PARP and claudin-1 in IHESC cells.
Had no significant effect on EGFR, FN, or α-SMA levels in IHESC cells.

Immunofluorescence

Cell Line: Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC)
Concentration: 13 μM
Incubation Time: 12 h
Result: Significantly reduced fluorescence intensity of COL1A1, N-cadherin, and TWIST1 compared to untreated controls in both IHEEC and IHESC cells.
Caused a substantial decrease in filamentous actin structures in treated cells as shown by phalloidin staining.
体内研究
(In Vivo)

DIM-3,5-Cl2 (2.5 mg/kg;腹腔注射;每日;连续 34 天) 以 2.5 mg/kg 的剂量每日给药、连续 34 天,可显著降低子宫内膜异位症病灶的生长,抑制细胞增殖,促进细胞凋亡,下调病灶中的 Nr4a1 和 Nr4a2 表达,且在手术诱导的 Mus musculus (小家鼠) 子宫内膜异位症模型中不会引发明显毒性。
DIM-3,5-Cl2 (2.5-7.5 mg/kg/天;腹腔注射;每日给药;连续 21 天) 可显著抑制同源 C57BL/6 小鼠体内 MC-38 结肠肿瘤的生长,下调肿瘤 PD-L1 的表达,并逆转肿瘤浸润淋巴细胞 (TILs) 和脾脏 CD8+ T 细胞的耗竭状态。

Animal Model: FVB/NJ (female, 6 weeks old, surgically induced endometriosis)
Dosage: 2.5 mg/kg
Administration: i.p.; daily; 34 consecutive days
Result: Significantly reduced ectopic lesion volume compared to vehicle control.
Significantly inhibited lesion growth as measured by luciferase imaging, while vehicle-treated mice showed continuous lesion growth.
Significantly reduced Ki-67 expression in stromal cells of ectopic lesions; Ki-67 expression in epithelial cells was not significantly affected.
Significantly increased TUNEL-positive (apoptotic) cells in ectopic lesions.
Significantly reduced Nr4a1 expression in both epithelial and stromal cells of ectopic lesions; significantly reduced Nr4a2 expression in stromal cells, with no significant effect on epithelial Nr4a2 expression.
Did not cause body weight loss, and liver panel analysis showed no evidence of liver damage compared to vehicle control.
Animal Model: C57BL/6 (female, 4-6 weeks old, subcutaneous implantation of MC-38 colon cancer cells)
Dosage: 2.5 mg/kg/day; 7.5 mg/kg/day
Administration: i.p.; daily; 21 days
Result: Significantly decreased tumor volumes and tumor weights relative to controls.
Showed no treatment-related toxicity, with treated mice showing a slight increase in body weight.
Decreased expression of NR4A1 and PD-L1 in tumor lysates at 2.5 mg/kg/day dose.
Significantly increased the percentage of CD8+ T-cells in tumor-infiltrating lymphocytes (TILs) at 2.5 mg/kg/day dose.
Decreased the percentage of CD8+ T-cells expressing the T-cell exhaustion markers PD-1, 2B4, and TIM3, and decreased the percentage of CD8+ T-cells co-expressing PD-1 and TIM3 in TILs at 2.5 mg/kg/day dose.
Decreased mRNA expression of NR4A1, TOX, TOX2, and NFAT, and increased mRNA expression of interferon γ, granzyme B, perforin, and T-Bet in CD8+ T-cells isolated from TILs at 2.5 mg/kg/day dose.
Significantly increased cell percentages, decreased the percentage of cells expressing PD-1, 2B4, TIM3, and PD-1/TIM3, increased the percentage of Treg cells, increased the percentage of cells expressing T-Bet and TOX/TOX2, and decreased the percentage of cells expressing NFAT1 in splenic CD8+ T-cells at 2.5 mg/kg/day dose.
性状 固体
颜色 White to off-white

化学信息

分子量 391.29
分子式 C23H16Cl2N2
CAS No. 2595179-74-9

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (255.56 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.5556 mL12.7782 mL25.5565 mL63.8912 mL
5 mM0.5111 mL2.5556 mL5.1113 mL12.7782 mL
10 mM0.2556 mL1.2778 mL2.5556 mL6.3891 mL
15 mM0.1704 mL0.8519 mL1.7038 mL4.2594 mL
20 mM0.1278 mL0.6389 mL1.2778 mL3.1946 mL
25 mM0.1022 mL0.5111 mL1.0223 mL2.5556 mL
30 mM0.0852 mL0.4259 mL0.8519 mL2.1297 mL
40 mM0.0639 mL0.3195 mL0.6389 mL1.5973 mL
50 mM0.0511 mL0.2556 mL0.5111 mL1.2778 mL
60 mM0.0426 mL0.2130 mL0.4259 mL1.0649 mL
80 mM0.0319 mL0.1597 mL0.3195 mL0.7986 mL
100 mM0.0256 mL0.1278 mL0.2556 mL0.6389 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础